Dealing with COVID 2.0, New IDSA Guidelines, and More!

How to Deal with COVID 2.0? In spite of five billion individuals fully vaccinated with COVID-19 vaccines, in 2022, more than 651 million people were infected and over 6.6 million died due to the disease. Given the sudden surge of cases in China and Japan over the last few days, join eminent pulmonary and critical care medicine specialist Dr. Gopi Chand Khilnani in our exclusive webinar to know how to deal with the new wave. Watch Now IDSA's COVID-19 Treatment Guidelines, 2022 Infectious Diseases Society of America (IDSA) guideline panel has issued 32 recommendations regarding the treatment and management of COVID-19 patients belonging to the following categories: Patients hospitalized with mild-to-moderate, severe but not critical, and critical disease. Read them here. Read the Guidelines Do mRNA Vaccines Induce Immune Response in Multiple Myeloma and B-cell Lymphoma Patients?� COVID-19 vaccine-induced immune responses in hematologic malignancy patients have not been adequately studied, despite their increased susceptibility to the infection. A longitudinal study compared immune responses generated by BNT162b2 mRNA vaccine doses in healthy control and patients with multiple myeloma and B-cell lymphoma (treated group). Read to know the findings! Know the Findings New Biomarker for Acute COVID-19 Though several vaccines have proven effective in reducing COVID-19 cases, the emergence of new variants, declining immunity, and limited distribution of the vaccines necessitate the development of robust diagnostics for the disease. Know about a new biomarker that could be a target for diagnosing, monitoring, and therapy! Know the Biomarker Docplexus: One of the world's largest online communities Pune - 411025, INDIA info@docplexus.co.in | +91-98500 36954 You received this mail because you opted-in to receive promotional mails from Docplexus. Change email preference.